Avet Pharma Announces the Launch of Glycopyrrolate Tablets
Eatontown, NJ, July, 25 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Glycopyrrolate immediate-release 1 and 2mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products. Glycopyrrolate is the AB rated generic equivalent to the anticholinergic drug Robinul®. It is indicated for adjunctive therapy in the treatment of peptic ulcer. According to IMS data for the twelve-months ended May 2017, the U.S. market for Glycopyrrolate tablets is approximately $18.4 million.